[1]刘清.多发性骨髓瘤患者血清HMGB1、FIB、β2-MG表达特征及临床价值[J].陕西医学杂志,2026,(3):328-333,338.[doi:DOI:10.3969/j.issn.1000-7377.2026.03.006]
　LIU Qing.Expression characteristics and clinical value of HMGB1,FIB and β2-MG in serum of patients with multiple myeloma[J].,2026,(3):328-333,338.[doi:DOI:10.3969/j.issn.1000-7377.2026.03.006]
点击复制

多发性骨髓瘤患者血清HMGB1、FIB、β2-MG表达特征及临床价值

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年3期
页码:
328-333,338
栏目:
临床研究
出版日期:
2026-03-05

文章信息/Info

Title:
Expression characteristics and clinical value of HMGB1,FIB and β2-MG in serum of patients with multiple myeloma
作者:
刘清
（南京医科大学附属苏州医院血液科，江苏 苏州 215000）
Author(s):
LIU Qing
(Department of Hematology,Suzhou Hospital,Nanjing Medical University,Suzhou 215000,China)
关键词:
多发性骨髓瘤; 高迁移率族蛋白B1; 纤维蛋白原; β2-微球蛋白; 预后
Keywords:
Multiple myeloma; High mobility group protein B1; Fibrinogen; β2-microglobulin; Prognosis
分类号:
R 733.3
DOI:
DOI:10.3969/j.issn.1000-7377.2026.03.006
文献标志码:
A
摘要:
目的：探讨多发性骨髓瘤患者（MM）血清高迁移率族蛋白B1（HMGB1）、纤维蛋白原（FIB）、β2-微球蛋白（β2-MG）表达特征及临床价值。方法：选取MM患者137例为研究组，选取体检健康者137例为对照组。国际分期系统（ISS）分期中，研究组Ⅰ期42例，Ⅱ期30例，Ⅲ期65例。随访3年，按照MM患者的生存情况又将研究组分为生存组（93例）和死亡组（44例）。比较各组血清HMGB1、FIB、β2-MG水平，并分析MM患者预后的影响因素以及三者对MM患者预后的预测价值。结果：与对照组比较，研究组血清HMGB1、FIB、β2-MG水平更高（均P<0.05）。不同临床分期患者血清HMGB1、FIB、β2-MG水平随分期的提高而升高（均P<0.05）。与存活组比较，死亡组血清HMGB1、FIB、β2-MG水平更高（均P<0.05）。血清HMGB1、FIB、β2-MG水平为MM患者预后的影响因素（均P<0.05）。血清HMGB1、FIB、β2-MG水平对MM患者死亡均有一定预测价值，且三项联合价值更高（均P<0.05）。结论：MM患者血清HMGB1、FIB、β2-MG水平呈高表达，且随临床分期提高而升高，三项联合对MM患者的预后具有良好的预测价值。
Abstract:
Objective:To investigate the expression characteristics and clinical value of serum high mobility group protein B1 (HMGB1),fibrinogen (FIB),and β2-microglobulin (β2-MG) in patients with multiple myeloma (MM).Methods：A total of 137 patients with MM were selected as the study group,and 137 healthy individuals undergoing physical examinations were selected as the control group.Among the study group,42 cases were in stageⅠ,30 cases in stageⅡ,and 65 cases in stageⅢ according to the ISS.The study group was followed up for 3 years and further divided into the survival group (93 cases) and the death group (44 cases) based on the survival status of MM patients.The levels of serum HMGB1,FIB,and β2-MG in each group were compared,and the influencing factors of prognosis in MM patients and the predictive value of the three for the prognosis of MM patients were analyzed.Results:Compared with the control group,the serum levels of HMGB1,FIB,and β2-MG in the study group were higher (all P<0.05).The serum levels of HMGB1,FIB,and β2-MG in patients of different clinical stages increased with the advancement of the stage (all P<0.05).Compared with the survival group,the serum levels of HMGB1,FIB,and β2-MG in the death group were higher (all P<0.05).Serum levels of HMGB1,FIB,and β2-MG were influencing factors for the prognosis of MM patients (all P<0.05).Serum levels of HMGB1,FIB,and β2-MG had certain predictive value for the death of MM patients,and the combined value of the three was higher (all P<0.05).Conclusion:Serum levels of HMGB1,FIB and β2-MG in MM patients are highly expressed,and they increase with the progression of the disease stage.The combination of these three indicators has a good predictive value for the prognosis of MM patients.

参考文献/References:

[1]杨春燕,黄倩,程盼盼,等.血清高迁移率族蛋白B1、胱抑素C及白细胞介素-17联合检测对多发性骨髓瘤患者肾损伤的诊断价值[J].中华生物医学工程杂志,2023,29(6):650-655.
[2]陈竹,范波胜,李光.急性缺血性脑卒中患者血管内介入治疗后S100A12、高迁移率族蛋白B1表达及与继发性脑出血的相关性分析[J].临床神经病学杂志,2023,36(1):18-21.
[3]赵思捷,余航,党珮珠,等.多发性骨髓瘤患者合并心包积液危险因素分析及列线图预测模型构建[J].陕西医学杂志,2024,53(12):1635-1639.
[4]孔祥红.骨髓瘤患者血清HMGB1、MIP-1α的表达与预后的关系[J].实用癌症杂志,2024,39(8):1387-1389.
[5]SCHUSTER S R,ITO S,HOYLE M,et al.Evaluation of elranatamab vs EPd,PVd,or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38-directed therapy:MagnetisMM-32[J].J Clin Oncol,2024,42(16):7576.
[6]郑波,哈丽达·夏尔甫哈孜,谈理.非酒精性脂肪性肝病患者血清HIF-1α、HMGB1和脂联素水平变化及其与颈动脉粥样硬化的关系研究[J].实用肝脏病杂志,2024,27(2):198-201.
[7]滕远,李莉娟,张连生.髓细胞白血病1抑制剂在多发性骨髓瘤治疗中的研究进展[J].陕西医学杂志,2024,53(6):858-861.
[8]陈施羊,周爱国,闫文龙,等.高迁移率族蛋白1通过PINK1/Parkin介导的线粒体自噬促进骨髓干细胞的趋化及成骨分化[J].骨科,2023,14(5):445-452.
[9]王辰辰,张倩倩,李静,等.化痰活血方治疗痰瘀痹阻型多发性骨髓瘤疗效及对患者血管内皮生长因子的影响[J].陕西中医,2022,43(5):588-591.
[10]丁文华,王育伟,邱景景,等.脑小血管病患者血清高迁移率族蛋白B1与焦虑症状的关系研究[J].中华老年心脑血管病杂志,2024,26(5):544-547.
[11]中国医师协会血液科医师分会,中华医学会血液学分会.中国多发性骨髓瘤诊治指南(2024年修订)[J].中华内科杂志,2024,63(12):1186-1195.
[12]SHAIKH S P,IRFAN S M,SHEIKH S S.Disease staging according to international scoring system in newly diagnosed patients with multiple myeloma[J].Pak J Med Sci,2019,35(1):90-94.
[13]夏艳艳,陈菲,朱宏,等.多发性骨髓瘤患者凝血指标水平的变化及意义[J].临床检验杂志,2023,41(6):428-431.
[14]李迎巧,高二超,王茂生.杨淑莲治疗多发性骨髓瘤经验[J].陕西中医,2022,43(5):628-631,652.
[15]JENSEN J L,RAKHMILEVICH A,HENINGER E,et al.Tumoricidal effects of macrophage-activating immunotherapy in a murine model of relapsed/refractory multiple myeloma[J].Cancer Immunol Res,2022,3(8):881-890.
[16]邓娜,杨明珍,吴冠宇,等.血清β2-MG、sRAGE联合PNI对初治多发性骨髓瘤患者死亡的预测价值[J].现代生物医学进展,2023,23(12):2332-2336.
[17]李永莉,傅琼瑶,赵莲,等.多发性骨髓瘤患者血清HSP90 mRNA、β2-MG的表达水平及其与患者预后的关系[J].现代肿瘤医学,2023,31(10):1875-1879.
[18]CHEN R,YANG J,MAO Y.Antibody-mediated nanodrug of proteasome inhibitor carfilzomib boosts the treatment of multiple myeloma[J].Biomacromolecules,2023,24(11):5371-5380.
[19]钱晗,袁鸿玲,张婷,等.血清ADA联合GLB、CREA、β2-MG、HGB在初诊多发性骨髓瘤中的临床意义[J].中国实验血液学杂志,2024,32(3):780-788.
[20]邱爽,孔卓,王芳.Cys C、C1q、β2-MG、Urea、UA检测对初诊多发性骨髓瘤患者合并肾损伤的诊断价值[J].医学研究杂志,2024,53(4):138-142.
[21]张小薇,林鸣深,李洋.Hcy、β2-MG和造血评分系统与多发性骨髓瘤患者预后的关系及预测价值[J].临床血液学杂志,2024,37(4):263-267.
[22]陆亚军,南萍,龚富婷,等.血清β2-MG联合PCT预测多发性骨髓瘤化疗患者肺部感染的价值[J].中国国境卫生检疫杂志,2023,46(2):183-187.
[23]潘亚晶,董玉倩,陈素洁.CD28+、CD56+在多发性骨髓瘤患者中的表达及其对预后的评估价值[J].实用癌症杂志,2024,39(9):1457-1460.
[24]赵冰妮,董春霞,康建民,等.多发性骨髓瘤合并静脉血栓栓塞症的危险因素分析[J].中国实验血液学杂志,2023,31(4):1100-1107.
[25]李辉锋,丁琪,毛永炎.血清β2-MG、IL-17、FLC联合检测对多发性骨髓瘤早期肾损伤的诊断价值分析[J].实用癌症杂志,2024,39(5):781-784.

相似文献/References:

[1]朱清红,李德奎,罗 英.血清尿酸、β2微球蛋白和尿液轻链联合检测〖JZ〗在多发性骨髓瘤早期诊断中的应用[J].陕西医学杂志,2019,(9):1235.
　ZHU Qinghong,LI Dekui,LUO Ying..Combined detection of serum uric acid，β2 microglobulin and urine light chain〖JZ〗in early diagnosis of multiple myeloma[J].,2019,(3):1235.
[2]靳娟娟,姚 玉.MutT同系物1抑制剂对多发性骨髓瘤细胞增殖和凋亡的影响[J].陕西医学杂志,2021,50(8):934.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.008]
　JIN Juanjuan,YAO Yu.Effect of MutT homologue-1 inhibitor on proliferation and apoptosis of multiple myeloma cells[J].,2021,50(3):934.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.008]
[3]赵 瑾,胡海燕,周艳红.高迁移率族蛋白B1过表达对子宫内膜癌细胞增殖、周期和凋亡的影响及机制研究[J].陕西医学杂志,2022,51(5):539.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.006]
　ZHAO Jin,HU Haiyan,ZHOU Yanhong.Effect and mechanism of HMGB1 overexpression on proliferation,cycle and apoptosis of endometrial cancer cells[J].,2022,51(3):539.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.006]
[4]封佑琪,陈 珊,汪鸿浩,等.高迁移率族蛋白B1在多发性硬化中的作用机制研究进展[J].陕西医学杂志,2022,51(7):902.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.033]
　FENG Youqi,CHEN Shan,WANG Honghao,et al.Research progress on mechanism of high mobility group protein B1 in multiple sclerosis[J].,2022,51(3):902.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.033]
[5]杜娟英,薛海鲸.多发性骨髓瘤患者血清微小RNA-424、可溶性晚期糖基化终末产物受体、c-kit受体蛋白检测及临床意义[J].陕西医学杂志,2022,51(12):1585.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.028]
　DU Juanying,XUE Haijing.Detection and clinical significance of serum miR-424,sRAGE and CD117 in patients with multiple myeloma[J].,2022,51(3):1585.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.028]
[6]张治业,余醒醒,张 璐,等.CD166对多发性骨髓瘤RPMI-8226细胞增殖、凋亡及自噬的影响实验研究[J].陕西医学杂志,2023,52(12):1675.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.010]
　ZHANG Zhiye,YU Xingxing,ZHANG Lu,et al.Effects of CD166 on proliferation,apoptosis and autophagy of multiple myeloma RPMI-8226 cells[J].,2023,52(3):1675.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.010]
[7]刘虹伶,王美佳,晏青霞.多发性骨髓瘤患者血清β2-微球蛋白、肿瘤坏死因子-α、乳酸脱氢酶检测及临床意义[J].陕西医学杂志,2024,(3):399.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.024]
　LIU Hongling,WANG Meijia,YAN Qingxia.Detection and clinical significance of serum β2-microglobulin,tumor necrosis factor-α and lactate dehydrogenase in patients with multiple myeloma[J].,2024,(3):399.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.024]
[8]滕 远,李莉娟,张连生.髓细胞白血病1抑制剂在多发性骨髓瘤治疗中的研究进展[J].陕西医学杂志,2024,(6):858.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.029]
　TENG Yuan,LI Lijuan,ZHANG Liansheng.Research progress of myeloid cell leukemia 1 inhibitors in treatment of multiple myeloma[J].,2024,(3):858.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.029]
[9]赵思捷,余 航,党珮珠,等.多发性骨髓瘤患者合并心包积液危险因素分析及列线图预测模型构建[J].陕西医学杂志,2024,(12):1635.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.009]
　ZHAO Sijie,YU Hang,DANG Peizhu,et al.Risk factors of multiple myeloma patients with pericardial effusion and construction of nomogram prediction model[J].,2024,(3):1635.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.009]
[10]徐丹,桂明才,周长华,等.老年突发性耳聋患者血清HMGB1、Cx43、TXB2水平变化及检测意义[J].陕西医学杂志,2025,54(8):1108.[doi:DOI:10.3969/j.issn.1000-7377.2025.08.020]
　XU Dan,GUI Mingcai,ZHOU Changhua,et al.Changes and detection significance of serum HMGB1,Cx43 and TXB2 levels in elderly patients with sudden deafness[J].,2025,54(3):1108.[doi:DOI:10.3969/j.issn.1000-7377.2025.08.020]

备注/Memo

备注/Memo:
国家自然科学基金资助项目（21705080）；江苏省重点研发计划项目（2021JZFY10923）
更新日期/Last Update: 2026-03-05